Emerging corticosteroid delivery platforms for treatment of diabetic macular edema

References

• Diabetes. Who.int. Published [2020; cited 2020 May 26]. https://www.who.int/news-room/fact-sheets/detail/diabetes
   Google Scholar
• Wong TY, Sabanayagama C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. Euretina lecture. Ophthalmologica. 2020;243:9–20.
   PubMed Web of Science ®Google Scholar
• Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339‐e349.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Yang Y, Lotery A, et al. Clinical evidence of the multifactorial nature of diabetic macular edema. Retina. 2018;38(2):343‐351.
   Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796‐1806.
   Google Scholar
• Goldman D, Waheed N, Duker J. Atlas of retinal OCT E-book. Philadelphia: Elsevier Health Sciences; 2017. p. 84–85.
   Google Scholar
• Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, et al. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014;10(2):100‐112.
   PubMedGoogle Scholar
• Stuart A Diabetic macular edema—personalizing treatment. EyeNet Magazine. 2016:45–49.
   Google Scholar
• Spooner KL, Guinan G, Koller S, et al. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes. 2019;12:1913‐1921.
   PubMed Web of Science ®Google Scholar
• Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37(4):893‐899.
   PubMed Web of Science ®Google Scholar
• Weinberg T, Loewenstein A. The role of steroids in treating diabetic macular oedema in the era of anti-VEGF. Eye. 2020;34:1003–1005.
   Web of Science ®Google Scholar
• Charles S, Corcoran KJ. The future of surgical retina in the era of medical retina commentary from a leader in vitreoretinal surgery. Retina Phys. 2017;14:23–25.
   Google Scholar
• Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–983.
   PubMed Web of Science ®Google Scholar
• Matthews D, Stratton I, Aldington S, et al., UK Prospective Diabetes Study Group. () Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122:1631–1640.
   PubMed Web of Science ®Google Scholar
• Takamura Y, Matsumura T, Ohkoshi K, et al. Functional and anatomical changes in diabetic macular edema after hemodialysis initiation: one-year follow-up multicenter study. Sci Rep. 2020;10(1):7788.
   PubMed Web of Science ®Google Scholar
• Wong T, Simo R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol. 2012;154:6–12.
   PubMed Web of Science ®Google Scholar
• Relhan N, Flynn HW Jr. The early treatment diabetic retinopathy study historical review and relevance to today’s management of diabetic macular edema. Curr Opin Ophthalmol. 2017;28(3):205–212.
   PubMed Web of Science ®Google Scholar
• Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6(4):511‐524.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789‐801.
   Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
   PubMed Web of Science ®Google Scholar
• The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Dugel PU. The cost-effectiveness of anti-VEGF treatment in diabetes it’s hard to put a price on letters and lines. Retin Physician. 2017;14:30–32.
   Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086.e2.
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044‐2052.
   Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Maguire MG, et al. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol. 2018;195:93‐100.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359.
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Cidlowski JA, Csaky KG, et al. Pharmacology of corticosteroids for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(1):1‐12.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533‐1538.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245–251.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064–1077.e35.
   PubMed Web of Science ®Google Scholar
• Gan IM, Ugahary LC, van Dissel JT, et al. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1186‐1189.
   Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, et al. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies. J Pharmacol Sci. 2018;138(4):219–232.
   PubMed Web of Science ®Google Scholar
• Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or dexamethasone implants for DME: 2-year results (The BEVORDEX study). Ophthalmology. 2016;123(6):1399–1401.
   PubMed Web of Science ®Google Scholar
• Sarao V, Veritti D, Boscia F, et al. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal. 2014;2014:989501.
   PubMedGoogle Scholar
• Campochiaro P, Brown D, Pearson A et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132.
   PubMed Web of Science ®Google Scholar
• Chawan-Saad J, Wu M, Wu A, et al. Corticosteroids for diabetic macular edema. Taiwan J Ophthalmol. 2019;9(4):233‐242.
   PubMedGoogle Scholar
• Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321(19):1880‐1894.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185‐222.
   PubMed Web of Science ®Google Scholar
• Amoaku W, Saker S, Stewart E. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye. 2015;29(9):1115–1130.
   PubMed Web of Science ®Google Scholar
• Mehta H, Fraser-Bell S, Yeung A, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. Br J Ophthalmol. 2016;100(7):1000‐1004.
   Web of Science ®Google Scholar
• Zhang X, Lai D, Bao S, et al. Triamcinolone acetonide inhibits p38MAPK activation and neuronal apoptosis in early diabetic retinopathy. Curr Mol Med. 2013;13(6):946–958.
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231–236.
   PubMed Web of Science ®Google Scholar
• Romero-Aroca P. Targeting the pathophysiology of diabetic macular edema. Diabetes Care. 2010;33(11):2484–2485.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–1161.
   PubMedGoogle Scholar
• Seah I, Zhao X, Lin Q, et al. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye. 2020:132–146.
   Web of Science ®Google Scholar
• Tang J, Kern T. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358.
   PubMed Web of Science ®Google Scholar
• Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65–84.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96(19):10836‐10841.
   Web of Science ®Google Scholar
• Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41(5):1153‐1158.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101‐108.
   Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156(5):1733–1739.
   PubMed Web of Science ®Google Scholar
• Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol. 2009;296(4):C821–C827.
   PubMed Web of Science ®Google Scholar
• Noma H, Mimura T, Yasuda K, et al. Role of inflammation in diabetic macular edema. Ophthalmologica. 2014;232(3):127‐135.
   Web of Science ®Google Scholar
• Vincent J, Mohr S. Inhibition of Caspase-1/Interleukin-1 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56(1):224–230.
   PubMed Web of Science ®Google Scholar
• Liu X, Ye F, Xiong H, et al. IL-1β Induces IL-6 production in retinal Müller cells predominantly through the activation of P38 MAPK/NF-κB signaling pathway. Exp Cell Res. 2015;331(1):223–231.
   PubMed Web of Science ®Google Scholar
• Rojas MA, Zhang W, Xu Z, et al. Interleukin 6 has a critical role in diabetes-induced retinal vascular inflammation and permeability. Invest Ophthalmol Vis Sci. 2011;52(14):1003.
   PubMedGoogle Scholar
• Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vision Res. 2017;139:93‐100.
   PubMed Web of Science ®Google Scholar
• Kowluru R, Zhong Q, Kanwar M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp Eye Res. 2010;90(5):617–623.
   PubMed Web of Science ®Google Scholar
• Messner M, Kurkov S, Jansook P, et al. Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm. 2010;387(1–2):199–208.
   PubMed Web of Science ®Google Scholar
• Robertson L A hot topic(al) for DME. The Ophthalmologist. [ Published 2020; cited 2020 May 30]. https://theophthalmologist.com/subspecialties/a-hot-topical-for-dme
   Google Scholar
• Oculis | phase 2 study results of OCS-01: an effective topical therapeutic for DME. Oculis.com. [ Published 2020; cited 2020 Mar 23]. https://oculis.com/2020/02/10/a-phase-2-study-of-ocs-01-an-effective-topical-treatment-for-dme/
   Google Scholar
• Ohira A, Hara K, Jóhannesson G, et al. Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. Acta Ophthalmol. 2015;93(7):610‐615.
   Web of Science ®Google Scholar
• EudraCT number 2017-001172-36 - Clinical trial results - EU clinical trials register. Clinicaltrialsregister.eu. [ Published 2020; cited 2020 May 30]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001172-36/results
   Google Scholar
• Schopf L, Enlow E, Popov A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1–2):63‐72.
   PubMedGoogle Scholar
• Kim T, Sall K, Holland EJ, et al. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Clin Ophthalmol. 2018;13:69‐86.
   PubMed Web of Science ®Google Scholar
• Exploratory study of KPI-121 effect on intra- or subretinal fluid due to retinal vein occlusion/diabetic macular edema. Clinicaltrials.gov. [cited 2020 Mar 22]. https://clinicaltrials.gov/ct2/show/NCT02245516
   Google Scholar
• Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers (Basel). 2011;3(1):193–221.
   Web of Science ®Google Scholar
• Pontes de Carvalho RA, Krausse ML, Murphree AL, et al. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47(10):4532‐4539.
   PubMed Web of Science ®Google Scholar
• Clinical Trials - 3TOPHTHALMICS. 3tophthalmics.com. [cited 2020 Mar 22] http://3tophthalmics.com/clinical-trials.html
   Google Scholar
• A phase I study of episcleral dexamethasone for treatment of macular edema. Clinicaltrials.gov. [cited 2020 Mar 22] https://clinicaltrials.gov/ct2/show/NCT04005430
   Google Scholar
• Sandahl M, Melton D, Tully J, et al. Evaluation of reproducibility and uniformity of PRINT implant manufacturing. Invest Ophthalmol Vis Sci. 2018;59(9):5671.
   PubMed Web of Science ®Google Scholar
• Baker-Schena L. Drug delivery for the posterior segment. EyeNet Magazine. 2019;39–44.
   Google Scholar
• Tully J, Williams S, Melton D, et al. AR-1105 dexamethasone extended release and pharmacokinetics in the non-human primate. Invest Ophthalmol Vis Sci. 2018;59(9):5673.
   Web of Science ®Google Scholar
• Study assessing AR-1105 in subjects with macular edema due to retinal vein occlusion (RVO). ClinicalTrials.gov. [ Published 2020; cited 2020 May 31]. https://clinicaltrials.gov/ct2/show/NCT03739593
   Google Scholar
• Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol. 2016;16:142.
   PubMed Web of Science ®Google Scholar
• Optina - Ampio Pharmaceuticals. Ampio pharmaceuticals. [cited 2020 Mar 22]. https://ampiopharma.com/pipeline/optina/
   Google Scholar
• Stewart MW, Flynn HW Jr, Schwartz SG, et al. Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv. 2016;13(9):1277‐1287.
   PubMed Web of Science ®Google Scholar
• Thomas GW, Rael LT, Bar-Or R, et al. Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics. Biochem Biophys Res Commun. 2012;421(4):707‐712.
   PubMed Web of Science ®Google Scholar
• danazol study group, Bar-Or D, Orlando A, Singer M. Potential beneficial effect of low-dose danazol in combination with renin-angiotensin system inhibitors in diabetic macular oedema. Acta Ophthalmol. 2017;95(7):e665–e667.
   PubMed Web of Science ®Google Scholar
• AP-05-002 A safety and efficacy study of oral danazol (a previously approved drug)in the treatment of diabetic macular edema. Clinicaltrials.gov. [cited 2020 Mar 22]. https://clinicaltrials.gov/ct2/show/NCT01821677
   Google Scholar
• Patane MA, Cohen AE, Sheppard JD, et al. Ocular iontophoresis for drug delivery could this method work for dosing posterior segment therapeutics? Retina Today. 2011;64–66.
   Google Scholar
• EyeGate pharma treats first patient in phase 1b/2a trial of EGP-437 in macular edema | eyegate pharma. Eyegatepharma.com. [Published 2015; cited 2020 Mar 22] http://www.eyegatepharma.com/press-release/eyegate-pharma-treats-first-patient-in-phase-1b-2a-trial-of-egp-437-in-macular-edema/
   Google Scholar
• EyeGate announces interim data from phase 1b/2a clinical trial of iontophoretic EGP-437 ophthalmic solution in macular edema patients | eyegate pharma. Eyegatepharma.com. [ Published 2015; cited 2020 Mar 22]. http://www.eyegatepharma.com/uncategorized/eyegate-announces-interim-data-from-phase-1b-2a-clinical-trial-of-iontophoretic-egp-437-ophthalmic-solution-in-macular-edema-patients/
   Google Scholar
• Open-label, multi-center, phase 1b/2a clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution in patients with macular edema. ClinicalTrials.gov. [cited 2020 Mar 22]. https://clinicaltrials.gov/ct2/show/NCT02485249
   Google Scholar
• Andrés-Guerrero V, Zong M, Ramsay E, et al. Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology. J Control Release. 2015;211:105‐117.
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Tabata Y, Kimura H, et al. Recent advances in intraocular drug delivery systems. Recent Pat Drug Deliv Formul. 2011;5(1):1–10.
   PubMedGoogle Scholar
• Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–1582.
   PubMed Web of Science ®Google Scholar
• Szilárd KL. Sustained- release corticosteroid delivery systems implant technology offers promising solutions to the burden of repeated injections for retinal diseases. Retina Today. 2010;44–46.
   Google Scholar
• Daull P, Paterson CA, Kuppermann BD, et al. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013;29(2):258‐269.
   PubMed Web of Science ®Google Scholar
• Santen reports fiscal 2016 consolidated performance. Ssl4.eir-parts.net. [ Published 2017; cited 2020 Mar 22]. https://ssl4.eirparts.net/doc/4536/tdnet/1467021/00.pdf
   Google Scholar
• Wang J, Jiang A, Joshi M, et al. Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm. 2013;2013:780634.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Eliott D, Cantrill HL, et al. I-VationTM TA: 24-month clinical results of the phase I safety and preliminary efficacy study. Invest Ophthalmol Vis Sci. 2009;50(13):4332.
   Google Scholar
• Enrollment in phase IIb clinical trial for I-vation(TM) TA (MK-0140) suspended pending review of study design by Merck & Co., Inc. | Biospace. BioSpace. [ Published 2008. cited 2020 Mar 22]. https://www.biospace.com/article/releases/enrollment-in-phase-iib-clinical-trial-for-i-vation-tm-ta-mk-0140-suspended-pending-review-of-study-design-by-merck-and-co-inc-/
   Google Scholar
• Barbieri R. New therapy for endometriosis. N Engl J Med. 1988;318(8):512–514.
   PubMed Web of Science ®Google Scholar
• Colston Wentz A. Adverse effects of danazol in pregnancy. Ann Intern Med. 1982;96(5):672–673.
   PubMed Web of Science ®Google Scholar